Well, it is BS. They’ve put ALL the 008 endpoints into the 002 trial so their line that cost increases are just due to FDA safety monitoring is bumpkin. You’d have to think why 008 at all, when now every patient has to do MRI’s etc. and they haven’t even done any analysis on 008.
also, there is now a six week opioid washout period before dosing.
PAR Price at posting:
$1.10 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)